Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

After a 20% stock plunge, Denmark's prized drugmaker triggers fears over jobs, confidence, and consumer spending.

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

COPENHAGEN, DENMARK (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that ...

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Pharmaceutical titan, Novo Nordisk A/S NVO, has had a significant impact on Denmark’s employment landscape, surpassing initial projections, as revealed by a report from the Economic Councils ...

Novo Nordisk , the maker of weight-loss drug Wegovy, earlier this month bought a 200-acre site in Denmark's third largest city Odense and will begin preparatory excavation works for a potential ...

Bagsværd, Denmark, 16 December 2024– Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark.

Heidelberg, Germany-based research institute BioMed X announced a new collaboration with Denmark’s Novo Nordisk, which aims ...

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...